Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Breast Cancer Metastatic × Anastrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 67 Neoplasms 7 Breast Neoplasms, Male 4 Neoplasm Metastasis 3 Carcinoma, Intraductal, Noninfiltrating 3 Arthralgia 3 Triple Negative Breast Neoplasms 2 Sexual Dysfunction, Physiological 1 Seizures 1 Recurrence 1 Pain 1 Osteoporosis 1 Obesity 1 Multiple Endocrine Neoplasia Type 1 1 Lethal Congenital Contracture Syndrome 2 1 Joint Diseases 1 Invasive Breast Cancer 1 Hypogonadism 1 Granulosa Cell Ovarian Cancer 1 Fractures, Bone 1 Erectile Dysfunction 1 Epilepsy 1 Carcinoma, Non-Small-Cell Lung 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Advanced Metastatic Breast Cancer 1 Advanced Breast Carcinoma 1

Interventions

tusamitamab ravtansine 1 nirogacestat 1 exemestane 1 Tamoxifen 1 Letrozole 1 Gemcitabine 1 Fulvestrant 1 Docetaxel 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡